{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T01:58:56Z","timestamp":1693360736488},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,2,17]],"date-time":"2018-02-17T00:00:00Z","timestamp":1518825600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s40256-018-0264-5","type":"journal-article","created":{"date-parts":[[2018,2,17]],"date-time":"2018-02-17T01:22:44Z","timestamp":1518830564000},"page":"143-151","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Evaluating the Safety and Tolerability of Sacubitril\/Valsartan for HFrEF Managed Within a Pharmacist Clinic"],"prefix":"10.1007","volume":"18","author":[{"given":"Elizabeth K.","family":"Pogge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay E.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,17]]},"reference":[{"issue":"10","key":"264_CR1","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","volume":"135","author":"EJ Benjamin","year":"2017","unstructured":"Benjamin EJ, Blaha MJ, Chiuve ST, et al. Heart disease and stroke statistics- 2017 update: a report from the American Heart Association. Circulation. 2017;135(10):e146\u2013603.","journal-title":"Circulation"},{"key":"264_CR2","doi-asserted-by":"publisher","first-page":"e240","DOI":"10.1161\/CIR.0b013e31829e8807","volume":"128","author":"CW Yancy","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF\/AHA guidelines for the management of heart failure. A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128:e240\u2013327.","journal-title":"Circulation"},{"key":"264_CR3","unstructured":"Entresto [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2015."},{"issue":"6","key":"264_CR4","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.jchf.2014.09.001","volume":"2","author":"O Vardeny","year":"2014","unstructured":"Vardeny O, Miller R, Solomon SD. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure. JACC Heart Fail. 2014;2(6):663\u201370.","journal-title":"JACC Heart Fail"},{"key":"264_CR5","first-page":"85","volume-title":"Pharmacotherapy: a pathophysiologic approach","author":"RB Parker","year":"2014","unstructured":"Parker RB, Nappi JM, Cavallari LH. Chronic heart failure. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy: a pathophysiologic approach. 9th ed. New York: McGraw-Hill; 2014. p. 85\u2013122.","edition":"9"},{"issue":"7","key":"264_CR6","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","volume":"136","author":"CW Yancy","year":"2017","unstructured":"Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guidelines for the management of heart failure- a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines, and the Heart Failure Society of America. Circulation. 2017;136(7):e137\u201361.","journal-title":"Circulation"},{"issue":"22","key":"264_CR7","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1001\/archinte.163.22.2696","volume":"163","author":"SI McFarlane","year":"2003","unstructured":"McFarlane SI, Winer N, Sowers JR. Role of the natriuretic peptide system in cardiorenal protection. Arch Intern Med. 2003;163(22):2696\u2013704.","journal-title":"Arch Intern Med"},{"issue":"11","key":"264_CR8","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai A, et al. Angiotensin-neprilysin inhibitor versus enalapril in heart failure. N Engl J Med. 2014;371(11):993\u20131004.","journal-title":"N Engl J Med"},{"issue":"38","key":"264_CR9","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1093\/eurheartj\/ehv330","volume":"36","author":"PS Jhund","year":"2015","unstructured":"Jhund PS, Fu M, Bayram E, et al. Efficacy and safety of LCZ696 (sacubitril\/valsartan) according to age: insights from PARADIGM-HF. Eur Heart J. 2015;36(38):2576\u201384.","journal-title":"Eur Heart J"},{"issue":"15","key":"264_CR10","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1093\/eurheartj\/ehw570","volume":"38","author":"M Bohm","year":"2017","unstructured":"Bohm M, Young R, Jhund PS, et al. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril\/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. Eur Heart J. 2017;38(15):1132\u201343.","journal-title":"Eur Heart J"},{"issue":"10","key":"264_CR11","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1002\/ejhf.580","volume":"18","author":"O Vardeny","year":"2016","unstructured":"Vardeny O, Claggett B, Packer M, et al. Efficacy of sacubitril\/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. Eur Heart J. 2016;18(10):1228\u201334.","journal-title":"Eur Heart J"},{"issue":"3","key":"264_CR12","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1016\/j.cardfail.2010.10.009","volume":"17","author":"P Gastelurrutia","year":"2011","unstructured":"Gastelurrutia P, Benrimoj S, Espejo J, Tuneu L, Mangues MA, Bayes-Genis A. Negative clinical outcomes associated with drug-related programs in heart failure (HF) outpatients: impact of a pharmacist in a multidisciplinary HF clinic. J Card Fail. 2011;17(3):2217\u201323.","journal-title":"J Card Fail."},{"key":"264_CR13","first-page":"A17948","volume":"134","author":"O Vardeny","year":"2016","unstructured":"Vardeny O, Claggett B, Kachadourian J, et al. Reduced loop diuretic use in patients taking sacubitril\/valsartan compared with enalapril: the paradigm-HF study. Circulation. 2016;134:A17948.","journal-title":"Circulation"},{"issue":"20","key":"264_CR14","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1056\/NEJMra1703100","volume":"377","author":"DH Ellison","year":"2017","unstructured":"Ellison DH, Felker GM. Diuretic treatment in heart failure. N Engl J Med. 2017;377(20):1964\u201375.","journal-title":"N Engl J Med"},{"key":"264_CR15","doi-asserted-by":"crossref","unstructured":"Hormann SB, Davis LE, Pogge EK. From theory to practice: the diuretic potential of sacubitril\/valsartan: a tale of 2 patients. J Cardiovasc Nurs 2018;33(2):104\u201310.","DOI":"10.1097\/JCN.0000000000000451"},{"issue":"6","key":"264_CR16","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2143\/AC.58.6.2005315","volume":"58","author":"GP Alexopoulos","year":"2003","unstructured":"Alexopoulos GP, Anastosiou-Nana MI, Rapti AC, et al. Lowering of furosemide dosage after clinical stabilization in patients with congestive heart failure. ACTA Cardiol. 2003;58(6):513\u20137.","journal-title":"ACTA Cardiol"},{"key":"264_CR17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1161\/HYPERTENSIONAHA.116.08484","volume":"69","author":"TD Wang","year":"2017","unstructured":"Wang TD, Tan RS, Lee HY, et al. Effects of sacubitril\/valsartan (LCA696) on natriuresis, diuresis, blood pressures, and NT-proBNP in salt-sensitive hypertension. Hypertension. 2017;69:32\u201341.","journal-title":"Hypertension"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40256-018-0264-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-018-0264-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-018-0264-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,16]],"date-time":"2019-02-16T21:53:44Z","timestamp":1550354024000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40256-018-0264-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,17]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["264"],"URL":"https:\/\/doi.org\/10.1007\/s40256-018-0264-5","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,17]]},"assertion":[{"value":"17 February 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Elizabeth K. Pogge and Lindsay E. Davis declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}